Trial Profile
A phase II trial of farletuzumab in FRA positive, triple negative breast cancer patients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2016
Price :
$35
*
At a glance
- Drugs Farletuzumab (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
- 22 Feb 2016 New trial record
- 03 Feb 2016 According to a Morphotek media release, this trial is supported by a grant from U.S. Department of Defense.